| All Releases |
|---|
 |
United Therapeutics Corporation Reports First Quarter 2013 Financial Results
Apr 25, 2013
|
23.0 KB
|
| |
SILVER SPRING, Md., April 25, 2013 /PRNewswire/ --
Total Revenues of $245.1 million
Earnings per Share of $1.24 per Basic Share or $1.19 per Diluted Share
Earnings Before Non-Cash Charges of $2.76 per Basic Share, or $2.65 per Diluted Share
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results fo...
|
|
|
United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
Apr 18, 2013
|
7.7 KB
|
| |
SILVER SPRING, Md., April 18, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its first quarter 2013 financial results before market open on Thursday, April 25, 2013.
United Therapeutics will host a half-hour teleconference on Thursday, April 25, 2013, at 9:00 a.m. Eastern Time. The t...
|
|
|
United Therapeutics Announces Receipt Of Second Complete Response Letter For Oral Treprostinil NDA
Mar 25, 2013
|
8.4 KB
|
| |
SILVER SPRING, Md., March 25, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it received a second complete response letter from the United States Food and Drug Administration (FDA) declining to approve its new drug application (NDA) for treprostinil diolamine extended release tablets (oral treprostinil) for...
|
|
|
United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
Feb 26, 2013
|
338.5 KB
|
| |
Total Annual Revenues of $916.1 million
Annual Earnings per Share of $5.84 per Basic Share or $5.71 per Diluted Share
Annual Earnings Before Non-Cash Charges of $9.97 per Basic Share or $9.75 per Diluted Share
Silver Spring, MD, February 26, 2013: Unit...
|
|
|
United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
Feb 19, 2013
|
7.6 KB
|
| |
SILVER SPRING, Md., Feb. 19, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its fourth quarter and annual 2012 financial results before market open on Tuesday, February 26, 2013.
United Therapeutics will host a half-hour teleconference on Tuesday, February 26, 2013, at 9:00 a.m. Easte...
|
|
|
United Therapeutics Announces FDA Acceptance of Resubmission of Oral Treprostinil NDA
Feb 14, 2013
|
8.0 KB
|
| |
SILVER SPRING, Md., Feb. 14, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for treprostinil diolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hyperten...
|
|
|
United Therapeutics Announces Additional $420 Million Share Repurchase Program
Feb 4, 2013
|
9.9 KB
|
| |
SILVER SPRING, Md., Feb. 4, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that its Board of Directors authorized the repurchase of up to an additional $420 million of the company's common stock. This program will become effective on March 4, 2013, and will remain open for up to one year. Purchases may be made...
|
|
|
United Therapeutics Corporation Reports Third Quarter 2012 Financial Results
Nov 1, 2012
|
26.5 KB
|
| |
SILVER SPRING, Md., Nov. 1, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2012.
"It is certainly gratifying to see us closely approach, for the first time, a revenue run rate of one billion dollars per year," said Martine Rothblatt, Ph.D., U...
|
|
|
United Therapeutics Corporation To Announce Third Quarter 2012 Financial Results Before Market Open On Thursday, November 1, 2012
Oct 25, 2012
|
7.7 KB
|
| |
SILVER SPRING, Md., Oct. 25, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its third quarter 2012 financial results before market open on Thursday, November 1, 2012.
United Therapeutics will host a half-hour teleconference on Thursday, November 1, 2012, at 9:00 a.m. Eastern Time. Th...
|
|
|
United Therapeutics Announces Receipt Of Complete Response Letter For Oral Treprostinil NDA
Oct 23, 2012
|
9.6 KB
|
| |
SILVER SPRING, Md., Oct. 23, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it received a complete response letter from the United States Food and Drug Administration (FDA) declining to approve its new drug application (NDA) for treprostinil diethanolamine extended release tablets (oral treprostinil) for th...
|
|
|
United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
Sep 20, 2012
|
13.1 KB
|
| |
SILVER SPRING, Md., Sept. 20, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has signed an exclusive agreement with Ascendis Pharma A/S to apply Ascendis Pharma's proprietary TransCon technology platform to United Therapeutics' treprostinil molecule, the active ingredient in Remodulin® (treprostinil...
|
|
|
United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
Jul 26, 2012
|
23.7 KB
|
| |
SILVER SPRING, Md., July 26, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2012.
"I am pleased with our second quarter results, which reflect the continued strength of our core business," remarked Martine Rothblatt, Ph.D., United Therapeutics' C...
|
|
|
United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
Jul 19, 2012
|
7.7 KB
|
| |
SILVER SPRING, Md., July 19, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its second quarter 2012 financial results before market open on Thursday, July 26, 2012.
United Therapeutics will host a half-hour teleconference on Thursday, July 26, 2012, at 9:00 a.m. Eastern Time. The tel...
|
|
|
United Therapeutics Announces Additional $100 Million Share Repurchase Program
Jun 27, 2012
|
8.7 KB
|
| |
SILVER SPRING, Md., June 27, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that its Board of Directors authorized the repurchase of up to an additional $100 million of the company's common stock. This program will become effective on July 31, 2012, and will remain open for up to one year. Purchases may be ma...
|
|
|
United Therapeutics Corporation Reports First Quarter 2012 Financial Results
Apr 26, 2012
|
24.1 KB
|
| |
SILVER SPRING, Md., April 26, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the first quarter ended March 31, 2012.
"I am pleased with our strong first quarter results," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "This is an imp...
|
|
|
United Therapeutics Corporation To Announce First Quarter 2012 Financial Results Before Market Open On Thursday, April 26, 2012
Apr 19, 2012
|
7.7 KB
|
| |
SILVER SPRING, Md., April 19, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its first quarter 2012 financial results before market open on Thursday, April 26, 2012.
United Therapeutics will host a half-hour teleconference on Thursday, April 26, 2012, at 9:00 a.m. Eastern Time. The t...
|
|
|
United Therapeutics Files Lawsuit Against Sandoz for Infringement of Remodulin Patents
Mar 15, 2012
|
9.7 KB
|
| |
SILVER SPRING, Md, March 15, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Sandoz Inc. (Sandoz) for infringement of U.S. Patent Nos. 5,153,222, 6,765,117 and 7,999,007 relating to United Therapeutics' product Remodulin...
|
|
|
Oral Treprostinil New Drug Application Accepted by FDA for Review
Feb 21, 2012
|
8.1 KB
|
| |
SILVER SPRING, Md., Feb. 21, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. Food and Drug Administration has accepted for review the new drug application (NDA) for treprostinil diethanolamine sustained release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension. The ND...
|
|
|
United Therapeutics Corporation Reports 2011 Fourth Quarter and Annual Financial Results
Feb 14, 2012
|
68.4 KB
|
| |
Total Annual Revenues of $743.2 million
Annual Earnings per Share of $3.81 per Basic Share or $3.67 per Diluted Share
Annual Earnings Before Non-Cash Charges of $6.36 per Basic Share or $6.12 per Diluted Share
Silver Spring, MD, February 14, 2012: United Therap...
|
|
|
United Therapeutics Corporation to Announce Fourth Quarter and Annual 2011 Financial Results Before Market Open on Tuesday, February 14, 2012
Feb 7, 2012
|
7.7 KB
|
| |
SILVER SPRING, Md., Feb. 7, 2012 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its fourth quarter and annual 2011 financial results before market open on Tuesday, February 14, 2012.
United Therapeutics will host a half-hour teleconference on Tuesday, February 14, 2012, at 9:00 a.m. Easter...
|
|
|
United Therapeutics' Press Release Archive is furnished solely for historical purposes. Statements made in any release posted here speak only as of the date of such release. We do not undertake any obligation to update any information contained in any release. Our business, financial condition, results of operations and prospects may have changed since the date of any release posted here.
